Skip to main content

Monkeypox (Mpox)

2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
2 programs
2
JynneosPhase 2
MVA-BNPhase 2
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
2 programs
JynneosPHASE_21 trial
MVA-BNPHASE_21 trial
Active Trials
NCT07199569Active Not Recruiting970Est. Nov 2026
NCT06549530Active Not Recruiting460Est. May 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Bavarian NordicJynneos
Bavarian NordicMVA-BN

Clinical Trials (2)

Total enrollment: 1,430 patients across 2 trials

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Start: Oct 2025Est. completion: Nov 2026970 patients
Phase 2Active Not Recruiting

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Start: Oct 2024Est. completion: May 2026460 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.